The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and preclinical biology without primary clinical data.
PubMed 36362069 · doi:10.3390/ijms232113282
What was done
The authors conducted a narrative review examining the role of thymosin β4 (Tβ4), its cleavage enzyme prolyl oligopeptidase (POP), and its active derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in tissue repair and fibrogenesis across the liver, kidney, heart, and lung.
What was found
The abstract provides no quantitative data or specific numerical effect sizes. It reports qualitatively that the Tβ4-POP-Ac-SDKP pathway operates across multiple organ systems to exert protective effects against extracellular matrix accumulation and fibrotic tissue remodeling.
Why it matters
Targeting the Tβ4-POP-Ac-SDKP pathway highlights a potential conserved biological mechanism for developing anti-fibrotic therapeutics across multiple organ systems.
Limits
The abstract describes a broad narrative synthesis without reporting a systematic literature search, inclusion criteria, quality appraisal, or study sample counts. The findings rely predominantly on preclinical and mechanistic models, leaving clinical dosing, safety, and therapeutic efficacy in humans unproven.
Cited by
- supports Thymosin beta-4 is a 43-amino-acid peptide being researched in oncology due to its implication in glioblastoma.